Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KOD 
Kodiak Sciences Inc (KOD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: KOD (4-star) is a STRONG-BUY. BUY since 95 days. Simulated Profits (107.80%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.25
1 Year Target Price $7.25
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 3 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 634.18% | Avg. Invested days 52 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 493.88M USD | Price to earnings Ratio - | 1Y Target Price 7.25 |
Price to earnings Ratio - | 1Y Target Price 7.25 | ||
Volume (30-day avg) 6 | Beta 2.45 | 52 Weeks Range 1.92 - 11.60 | Updated Date 09/15/2025 |
52 Weeks Range 1.92 - 11.60 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.38% | Return on Equity (TTM) -140.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 449647623 | Price to Sales(TTM) - |
Enterprise Value 449647623 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding 52821700 | Shares Floating 29509383 |
Shares Outstanding 52821700 | Shares Floating 29509383 | ||
Percent Insiders 5.52 | Percent Institutions 79.26 |
Upturn AI SWOT
Kodiak Sciences Inc
Company Overview
History and Background
Kodiak Sciences Inc. is a biopharmaceutical company founded in 2006. It focuses on developing novel therapeutics to treat high-prevalence retinal diseases. The company has evolved from an early-stage research firm to a clinical-stage company with a focus on its Antibody Biopolymer Conjugate (ABC) Platform.
Core Business Areas
- Retinal Disease Therapeutics: Development and commercialization of therapies targeting retinal diseases such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO).
Leadership and Structure
Kodiak Sciences is led by Victor Perlroth, MD, as CEO. The organizational structure includes research, clinical development, and commercial operations departments.
Top Products and Market Share
Key Offerings
- Tarcocimab Tedromil (KSI-301): Tarcocimab tedromil is an anti-VEGF antibody biopolymer conjugate being developed for the treatment of wet AMD, diabetic retinopathy, and RVO. It aims to provide longer-lasting efficacy with less frequent dosing. Currently in clinical trials, not yet commercially available, so no market share yet. Competitors include Regeneron's Eylea and Roche's Vabysmo.
Market Dynamics
Industry Overview
The retinal disease therapeutics market is large and growing, driven by an aging population and increasing prevalence of diabetes. The market is characterized by intense competition and high unmet need for longer-lasting therapies.
Positioning
Kodiak Sciences aims to differentiate itself through its ABC Platform, which has the potential to extend the durability of anti-VEGF therapies. If successful, the company could capture a significant share of the market.
Total Addressable Market (TAM)
The global retinal disease therapeutics market is projected to reach tens of billions of dollars annually. Kodiak Sciences aims to capture a portion of this TAM with its novel therapies, focusing on less frequent dosing regimens.
Upturn SWOT Analysis
Strengths
- Novel ABC Platform technology
- Potential for longer-lasting therapies
- Experienced management team
Weaknesses
- Reliance on a single lead product candidate
- Clinical trial execution risk
- High cash burn rate
Opportunities
- Successful clinical trial results for tarcocimab tedromil
- Partnerships with larger pharmaceutical companies
- Expansion of the ABC Platform to other therapeutic areas
Threats
- Competition from established anti-VEGF therapies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- REGN
- RHHBY
Competitive Landscape
Kodiak Sciences faces stiff competition from established players in the anti-VEGF market. Its competitive advantage lies in the potential for longer-lasting therapies, reducing the need for frequent injections.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D investments and clinical trial progress.
Future Projections: Future growth is dependent on the successful commercialization of tarcocimab tedromil and other pipeline products. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing tarcocimab tedromil through Phase 3 clinical trials and exploring new applications of the ABC Platform.
Summary
Kodiak Sciences is a clinical-stage biopharmaceutical company with a novel platform. Its lead candidate, tarcocimab tedromil, has the potential to disrupt the retinal disease therapeutics market if clinical trials are successful. However, the company faces significant risks related to clinical trial outcomes and competition. Success hinges on demonstrating superior efficacy and durability compared to existing therapies. The company needs to monitor its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and represents an opinion. It should not be considered investment advice. The information is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kodiak Sciences Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Chairman, CEO & President Dr. Victor Perlroth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 121 | Website https://kodiak.com |
Full time employees 121 | Website https://kodiak.com | ||
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.